TREATMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA – OUREXPERIENCE
Abstract
BACKGROUND Thrombotic thrombocytopenic purpura (TTP) is a rare disease. It develops as a consequence of abnormal metabolism of a disintegrin and matalloproteinase with thrombospondincomponents (ADAMTS13). Its clinical picture is heterogenous. Exchange plasmapheresisand various modes of immunosupression are essential for remission induction. Inspite oftreatment only 90 % of patients survive. The purpose of this paper is to present patients’data, clinical picture, treatment and outcome of patients with TTP. METHODS Data of 14 patinets was obtained using the Hipokrat computer program and analysedusing descriptive statistics. RESULTS We treated 14 patients who mainly presented with gastrointestinal and central nervoussystem symptoms and signs. Thirteen patients had idiopathic TTP and one had secondaryTTP. Patients with idiopathic TTP were treated with exchange plasmapheresis and corticosteroids. Primary resistant patients and those with relapses were either splenectomised(5 patients) or received rituximab (3 patients). CONCLUSIONS TTP is a rare disease with a heterogenous clinical presentation. We observed 100 %survival using standard treatment modes and relaps preventionDownloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
